Market Overview:
The global artificial blood products market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidences of trauma and accidents, increasing demand for blood substitutes, and technological advancements in the field of artificial blood products. The global artificial blood products market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into perfluorocarbon-based oxygen carrier (PFBOC) and hemoglobin-based oxygen carrier (HBOC). PFBOC held a dominant share in 2017 owing to its advantages over HBOC such as low viscosity which allows easy flow through small veins and capillaries; high solubility which helps it dissolve quickly in body fluids; long shelf life; non-toxicity; and ability to carry large volumes of oxygen. However, HBOCs are expected to grow at a higher CAGR during the forecast period due to their advantages over PFBOCs such as lower cost; ability to bind more oxygen than PFBOCs leading improved tissue perfusion; reduced incidence of adverse effects such as renal failure or pulmonary edema associated with use of PFBOCs.; and longer storage life than PFBOCs.
Product Definition:
Artificial blood products are substances that are used to replace or supplement natural blood. They can be used to improve the function of red blood cells, help with clotting, or provide other benefits. Artificial blood products are important because they can help save lives in emergency situations where there is a shortage of donated blood.
Perfluorocarbon-based Oxygen Carrier (PFBOC):
Perfluorocarbon-based oxygen carrier (PFBOC) is a perfluorocarbon with an oxygen content of approximately 15%. It has been used as an artificial blood product for the preparation of hemoglobin-based blood products. The demand for PFBOC in the artificial blood market has increased owing to its several advantages such as non-toxic, non-corrosive, and low cost over other traditional carriers such as RBCs or WBCs.
Hemoglobin-based Oxygen Carrier (HBOC):
The global heme-based oxygen carrier (HBOC) and it's usage in artificial blood products market size was valued at USD 6.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing demand for blood components across various end-use segments such as surgical procedures, emergency medicine, transfusion therapy, hemotherapy etc., is one of the key factors anticipated to boost growth over the coming years.
Application Insights:
The military segment dominated the market in terms of revenue share in 2017. The use of artificial blood products for military applications is gaining significant traction owing to several advantages offered such as ready availability, high efficiency and safety. Moreover, increasing demand for efficient oxygen carrying agents during training sessions and combat operations is expected to drive the segment over the forecast period.
Civil application accounted for a substantial share in 2017 due to rising awareness about O2 provisioning therapy options other than breathable airways that are used by patients with respiratory disorders or asthma at home without hospitalization or emergency room visits. Increasingly sophisticated artificial blood products enable safe use by patients at home without medical supervision which is further anticipated to propel their demand among civil users over the forecast period. Increasing R&D pertaining to HBOCs with improved hemodynamic properties will also have a positive impact on market growth among civil applications during future years.
Regional Analysis:
North America accounted for the largest share of over 40.0% in 2017 owing to the presence of well-established healthcare infrastructure, high awareness levels coupled with relatively higher patient pool undergoing surgeries are some factors attributing toward a large market share. Moreover, increasing R&D activities and technological advancements in this region are expected to fuel market growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period due to rising medical tourism and improving healthcare facilities at a domestic level which will lead towards an increase in demand for artificial blood products especially HBOCs. In addition, favorable government initiatives such as 100% FDI allowed under Foreign Direct Investment (FDI) policy by India's Ministry of Commerce & Industry is expected drive regional market growth during the forecast period.
Growth Factors:
- Increasing demand for artificial blood products in the treatment of various diseases and disorders.
- Rising prevalence of chronic diseases such as cancer, heart disease, and diabetes which require regular blood transfusions.
- Growing number of surgical procedures requiring blood transfusion for better patient outcomes.
- Technological advancements in the field of artificial blood products development that offer enhanced performance and safety profiles over traditional donor-derived blood products .
Scope Of The Report
Report Attributes
Report Details
Report Title
Artificial Blood Products Market Research Report
By Type
Perfluorocarbon-based Oxygen Carrier (PFBOC), Hemoglobin-based Oxygen Carrier (HBOC)
By Application
Military, Civil
By Companies
Aurum Biosciences Ltd., HEMARINA SA, HbO2 Therapeutics, KaloCyte Inc., SpheriTech Ltd., NuvOx Pharma, Aurum Biosciences Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Artificial Blood Products Market Report Segments:
The global Artificial Blood Products market is segmented on the basis of:
Types
Perfluorocarbon-based Oxygen Carrier (PFBOC), Hemoglobin-based Oxygen Carrier (HBOC)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Military, Civil
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aurum Biosciences Ltd.
- HEMARINA SA
- HbO2 Therapeutics
- KaloCyte Inc.
- SpheriTech Ltd.
- NuvOx Pharma
- Aurum Biosciences Ltd.
Highlights of The Artificial Blood Products Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Perfluorocarbon-based Oxygen Carrier (PFBOC)
- Hemoglobin-based Oxygen Carrier (HBOC)
- By Application:
- Military
- Civil
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Artificial Blood Products Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Artificial blood products are medical devices that help to replace lost or damaged blood. They can be used in a variety of ways, including during surgery and during childbirth.
Some of the key players operating in the artificial blood products market are Aurum Biosciences Ltd., HEMARINA SA, HbO2 Therapeutics, KaloCyte Inc., SpheriTech Ltd., NuvOx Pharma, Aurum Biosciences Ltd..
The artificial blood products market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Artificial Blood Products Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Artificial Blood Products Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Artificial Blood Products Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Artificial Blood Products Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Artificial Blood Products Market Size & Forecast, 2018-2028 4.5.1 Artificial Blood Products Market Size and Y-o-Y Growth 4.5.2 Artificial Blood Products Market Absolute $ Opportunity
Chapter 5 Global Artificial Blood Products Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Artificial Blood Products Market Size Forecast by Type
5.2.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
5.2.2 Hemoglobin-based Oxygen Carrier (HBOC)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Artificial Blood Products Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Artificial Blood Products Market Size Forecast by Applications
6.2.1 Military
6.2.2 Civil
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Artificial Blood Products Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Artificial Blood Products Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Artificial Blood Products Analysis and Forecast
9.1 Introduction
9.2 North America Artificial Blood Products Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Artificial Blood Products Market Size Forecast by Type
9.6.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
9.6.2 Hemoglobin-based Oxygen Carrier (HBOC)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Artificial Blood Products Market Size Forecast by Applications
9.10.1 Military
9.10.2 Civil
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Artificial Blood Products Analysis and Forecast
10.1 Introduction
10.2 Europe Artificial Blood Products Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Artificial Blood Products Market Size Forecast by Type
10.6.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
10.6.2 Hemoglobin-based Oxygen Carrier (HBOC)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Artificial Blood Products Market Size Forecast by Applications
10.10.1 Military
10.10.2 Civil
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Artificial Blood Products Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Artificial Blood Products Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Artificial Blood Products Market Size Forecast by Type
11.6.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
11.6.2 Hemoglobin-based Oxygen Carrier (HBOC)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Artificial Blood Products Market Size Forecast by Applications
11.10.1 Military
11.10.2 Civil
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Artificial Blood Products Analysis and Forecast
12.1 Introduction
12.2 Latin America Artificial Blood Products Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Artificial Blood Products Market Size Forecast by Type
12.6.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
12.6.2 Hemoglobin-based Oxygen Carrier (HBOC)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Artificial Blood Products Market Size Forecast by Applications
12.10.1 Military
12.10.2 Civil
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Artificial Blood Products Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Artificial Blood Products Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Artificial Blood Products Market Size Forecast by Type
13.6.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
13.6.2 Hemoglobin-based Oxygen Carrier (HBOC)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Artificial Blood Products Market Size Forecast by Applications
13.10.1 Military
13.10.2 Civil
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Artificial Blood Products Market: Competitive Dashboard
14.2 Global Artificial Blood Products Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aurum Biosciences Ltd.
14.3.2 HEMARINA SA
14.3.3 HbO2 Therapeutics
14.3.4 KaloCyte Inc.
14.3.5 SpheriTech Ltd.
14.3.6 NuvOx Pharma
14.3.7 Aurum Biosciences Ltd.